DrugCite
Search

CAP VORINOSTAT UNK

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Cap Vorinostat Unk Adverse Events Reported to the FDA Over Time

How are Cap Vorinostat Unk adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Cap Vorinostat Unk, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Cap Vorinostat Unk is flagged as the suspect drug causing the adverse event.

Most Common Cap Vorinostat Unk Adverse Events Reported to the FDA

What are the most common Cap Vorinostat Unk adverse events reported to the FDA?

Febrile Neutropenia
53 (2.37%)
Nausea
51 (2.28%)
Vomiting
38 (1.7%)
Pneumonia
37 (1.66%)
Diarrhoea
35 (1.57%)
Dehydration
33 (1.48%)
Pleural Effusion
30 (1.34%)
Thrombocytopenia
28 (1.25%)
Fatigue
25 (1.12%)
Pyrexia
25 (1.12%)
Cellulitis
24 (1.07%)
Show More Show More
Haemoglobin Decreased
23 (1.03%)
Asthenia
19 (.85%)
Myocardial Infarction
19 (.85%)
Hypokalaemia
18 (.81%)
White Blood Cell Count Decreased
18 (.81%)
Chills
17 (.76%)
Disease Progression
17 (.76%)
Fall
17 (.76%)
Platelet Count Decreased
17 (.76%)
Staphylococcal Infection
16 (.72%)
Acute Myeloid Leukaemia
15 (.67%)
Enterococcal Infection
15 (.67%)
Pancytopenia
15 (.67%)
Constipation
14 (.63%)
Hyperglycaemia
14 (.63%)
Lobar Pneumonia
14 (.63%)
Pulmonary Oedema
14 (.63%)
Anaemia
13 (.58%)
Hyperhidrosis
13 (.58%)
Abdominal Pain
12 (.54%)
Alanine Aminotransferase Increased
12 (.54%)
Headache
12 (.54%)
Hypertension
12 (.54%)
Infection
12 (.54%)
Insomnia
12 (.54%)
Respiratory Failure
12 (.54%)
Somnolence
12 (.54%)
Urinary Tract Infection
12 (.54%)
Atrial Fibrillation
11 (.49%)
Bacterial Infection
11 (.49%)
Blood Glucose Increased
11 (.49%)
Clostridial Infection
11 (.49%)
Confusional State
11 (.49%)
Haematocrit Decreased
11 (.49%)
Hypophagia
11 (.49%)
Urinary Retention
11 (.49%)
Aspartate Aminotransferase Increase...
10 (.45%)
Bradycardia
10 (.45%)
Dyspnoea
10 (.45%)
Electrocardiogram Qt Prolonged
10 (.45%)
Mastoiditis
10 (.45%)
Renal Failure Acute
10 (.45%)
Supraventricular Extrasystoles
10 (.45%)
Blood Creatinine Increased
9 (.4%)
Bundle Branch Block Right
9 (.4%)
Cardiac Failure Congestive
9 (.4%)
Cough
9 (.4%)
Device Related Infection
9 (.4%)
Haematemesis
9 (.4%)
Hypotension
9 (.4%)
Sepsis
9 (.4%)
Culture Urine Positive
8 (.36%)
Decreased Appetite
8 (.36%)
Erythema
8 (.36%)
Escherichia Bacteraemia
8 (.36%)
Furuncle
8 (.36%)
Gastrooesophageal Reflux Disease
8 (.36%)
Malignant Neoplasm Progression
8 (.36%)
Myocardial Ischaemia
8 (.36%)
Weight Decreased
8 (.36%)
Agitation
7 (.31%)
Blood Calcium Decreased
7 (.31%)
Blood Culture Positive
7 (.31%)
Chest Pain
7 (.31%)
Deep Vein Thrombosis
7 (.31%)
Electrocardiogram St Segment Abnorm...
7 (.31%)
Hyperbilirubinaemia
7 (.31%)
Mental Status Changes
7 (.31%)
Oropharyngeal Pain
7 (.31%)
Pericardial Effusion
7 (.31%)
Proctalgia
7 (.31%)
Rash
7 (.31%)
Respiratory Distress
7 (.31%)
Subdural Haematoma
7 (.31%)
Tachycardia
7 (.31%)
Condition Aggravated
6 (.27%)
Culture Wound Positive
6 (.27%)
Epididymitis
6 (.27%)
Gait Disturbance
6 (.27%)
Gastrointestinal Haemorrhage
6 (.27%)
Lung Infection
6 (.27%)
Lymphadenopathy
6 (.27%)
Mitral Valve Incompetence
6 (.27%)
Pain
6 (.27%)
Rash Pustular
6 (.27%)
Renal Failure
6 (.27%)
Sialoadenitis
6 (.27%)
Skin Lesion
6 (.27%)
Tenderness
6 (.27%)
Ventricular Extrasystoles
6 (.27%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Cap Vorinostat Unk, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cap Vorinostat Unk is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Cap Vorinostat Unk

What are the most common Cap Vorinostat Unk adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Cap Vorinostat Unk, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cap Vorinostat Unk is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Cap Vorinostat Unk According to Those Reporting Adverse Events

Why are people taking Cap Vorinostat Unk, according to those reporting adverse events to the FDA?

Acute Myeloid Leukaemia
83
Multiple Myeloma
24
Myelodysplastic Syndrome
22
Glioblastoma Multiforme
7
Chronic Lymphocytic Leukaemia
6
Non-small Cell Lung Cancer
5
Show More Show More
Medulloblastoma
4
Neuroblastoma
4
Mantle Cell Lymphoma
4
Breast Cancer
4
Diffuse Large B-cell Lymphoma
3
B-cell Lymphoma
3
Ovarian Cancer
3
Gastric Cancer
3
Hodgkins Disease
3
Bladder Cancer
2
Non-hodgkins Lymphoma Recurrent
2
Oesophageal Adenocarcinoma
2
Renal Cell Carcinoma
2
Prostate Cancer
2
Non-hodgkins Lymphoma
2
Neoplasm Malignant
2
Mycosis Fungoides
2
Metastasis
2
Follicle Centre Lymphoma, Follicula...
1
Prostate Cancer Metastatic
1
Glioblastoma
1
Nodal Marginal Zone B-cell Lymphoma
1
Prophylaxis Against Graft Versus Ho...
1
Drug Use For Unknown Indication
1
Oesophageal Cancer Metastatic
1
Metastases To Central Nervous Syste...
1
Prophylaxis
1
Graft Versus Host Disease
1
Breast Cancer Metastatic
1
Chronic Myeloid Leukaemia
1
Mesothelioma
1
Adenocarcinoma
1

Cap Vorinostat Unk Case Reports

What Cap Vorinostat Unk safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Cap Vorinostat Unk. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Cap Vorinostat Unk.